Published in final edited form as:

Mol Neurobiol. 2017 April ; 54(3): 2045–2059. doi:10.1007/s12035-016-9796-3.

Boosting Endogenous Resistance of Brain to Ischemia

Fen Sun¹, Stephen R. Johnson², Kunlin Jin¹, and Victor V. Uteshev¹

¹University of North Texas Health Science Center, Institute for Healthy Aging, Center for Neuroscience Discovery, 3500 Camp Bowie Blvd., Fort Worth, TX 76107

²Carbon Dynamics Institute, LLC, Sherman, IL 62711

Abstract

Most survivors of ischemic stroke remain physically disabled and require prolonged rehabilitation. However, some stroke victims achieve a full neurological recovery suggesting that human brain can defend itself against ischemic injury, but the protective mechanisms are unknown. This study used selective pharmacological agents and a rat model of cerebral ischemic stroke to detect endogenous brain protective mechanisms that require activation of $\alpha 7$ nicotinic acetylcholine receptors (nAChRs). This endogenous protection was found to be: 1) limited to less severe injuries; 2) significantly augmented by intranasal administration of a positive allosteric modulator of $\alpha 7$ nAChRs, significantly reducing brain injury and neurological deficits after more severe ischemic injuries; and 3) reduced by inhibition of calcium/calmodulin-dependent kinase-II. The physiological role of $\alpha 7$ nAChRs remains largely unknown. The therapeutic activation of $\alpha 7$ nAChRs after cerebral ischemia may serve as an important physiological responsibility of these ubiquitous receptors and holds a significant translational potential.

Keywords

PNU120596; PNU-120596; nicotinic receptors; choline; allosteric modulator; stroke; neuroprotection

Introduction

Choline and choline derivatives such as cytidine-5'-dihosphocholine (i.e., CDP-choline, also known as citicoline) stimulate brain phosphatidylcholine synthesis, tissue repair and neurological function and have been viewed as highly bio-available and safe treatments after ischemic stroke, traumatic brain injury and other neurological disorders. However, the recent failure of the International Citicoline Trial on Acute Stroke (ICTUS)[1], has dampened the enthusiasm for choline-based therapies in neurological disorders. Although choline and choline derivatives are important building blocks of cellular membranes in the brain, a different important property of endogenous choline may hold significant therapeutic potential [2-4]: i.e., the ability of choline to selectively activate $\alpha 7$ nicotinic acetylcholine receptors (nAChRs).

Corresponding author: Victor V. Uteshev (Victor.Uteshev@unthsc.edu).

Declaration of conflict of interest: The authors report no conflict of interest.

It is an intriguing concept that the mammalian brain can defend itself against ischemic injury and that the brain's inner capacity to resist ischemic injury can be elevated by the injury itself. In the absence of clinically effective post-stroke therapies, endogenous brain protection may serve as a compelling therapeutic guidance from nature. While post-stroke rehabilitation programs (e.g., targeted neural plasticity) can be highly effective,[5] the potential positive impact of a successful early post-stroke therapy on the patient progress cannot be overestimated because the majority of cell damage and death occur within the first two hours after the onset of stroke. Among early post-stroke pharmacological interventions, the strategies that enhance brain innate capacity to resist ischemic injury are especially attractive because they could allow clinicians to team up with endogenous protective mechanisms that are already in place to selectively target cerebral ischemic injury with a high spatiotemporal precision.[6,4,7]

The $\alpha 7$ nAChRs are commonly expressed in neuronal and non-neuronal tissues throughout the brain including brain regions that are highly susceptible to ischemic injury.[8-13] Despite their broad distribution in the brain, the physiological role of $\alpha 7$ nAChRs is not known, but the predominant absence of classical $\alpha 7$ nAChR synapses in the central nervous system suggests extensive pre- and/or extra-synaptic functions.[14] The existing literature indicates that activation of $\alpha 7$ nAChRs by endogenous (i.e., choline and ACh) or exogenous (e.g., nicotine) agonists benefits survival and function of individual neurons and neuronal networks in various *in vivo*, *ex vivo* and *in vitro* models of cerebral ischemic stroke, traumatic brain injury and other neurological disorders.[15,16,2,3,17,12,18-23] However, the normal physiological levels of extracellular choline ($<10 \mu\text{M}$)[24,25] and ACh ($<10 \text{nM}$)[26] are sub-threshold for $\alpha 7$ activation[27-29] due to the low potency of choline ($\text{EC}_{50} \sim 0.5 \text{ mM}$)[30] and ACh ($\text{EC}_{50} \sim 0.12 \text{ mM}$),[31] as well as their tendency to induce $\alpha 7$ desensitization:[32,28] $\text{IC}_{50}(\text{choline}) \sim 40 \mu\text{M}$ [28] and $\text{IC}_{50}(\text{ACh}) \sim 1.7 \mu\text{M}$. [31] As a result, the therapeutic effects of $\alpha 7$ agonists may develop tolerance.[33,34] Therefore, endogenous nicotinic agonists have been dismissed as therapeutic agents even though the extracellular concentration of choline can be considerably elevated by energy deprivation, cellular dysfunction, injury and death due to the cell membrane phosphatidylcholine breakdown[35-39,29,40] providing a large source of this selective $\alpha 7$ agonist. Significant elevations in the extracellular level of choline have been recently demonstrated by direct measurements in the peri-infarct areas after a middle cerebral artery occlusion (MCAO) model of cerebral ischemic stroke in rats.[37]

The positive allosteric modulation of $\alpha 7$ nAChRs has been proposed as a powerful alternative to the desensitizing and somewhat indiscriminate action of nicotinic agonists as an approach to counteracting neurocognitive deficits,[41,42] acute and chronic nociception[33,23] and cerebral ischemia.[2,3,6] There are two types of positive allosteric modulators (PAMs) of $\alpha 7$ nAChR. Both types potentiate $\alpha 7$ responses, but only the Type-II PAMs (abbreviated here as $\alpha 7$ -PAMs) reverses $\alpha 7$ desensitization. The Type-II PAMs, such as PNU120596 (abbreviated hereafter as PNU), are extremely selective for $\alpha 7$ nAChRs[6], but do not directly activate $\alpha 7$ nAChRs. Instead, PNU-like $\alpha 7$ PAMs enhance and prolong activation of $\alpha 7$ nAChRs by nicotinic agonists[41] including choline.[27,43]

We have previously reported that intravenous (i.v.) or subcutaneous (s.c.) PNU treatment up to 6 hrs after a transient 90 min suture MCAO, significantly reduced brain injury and neurological deficits in young adult rats.[2,3] We then have proposed that the therapeutic action of PNU most likely arises from augmenting the protective action of endogenous $\alpha 7$ agonists[2,3] after MCAO in a spatiotemporally restricted manner exactly where and when it is most needed: near the site and time of focal cerebral ischemia.[6,4] However, the direct evidence of endogenous $\alpha 7$ -dependent protective action and its enhancement by $\alpha 7$ -PAMs after MCAO have not been produced. In this study, we use selective pharmacological agents and a transient suture MCAO (tMCAO) in young adult rats to identify endogenous $\alpha 7$ -dependent protection that can be significantly augmented by PNU.

While the i.v. treatment provides an unrestricted access to blood circulation and thus, precise dose and time regimens can be ensured, it requires a fully functional cerebral circulation near the peri-infarct area to be fully effective. This may not be readily available after ischemic stroke even after a successful re-perfusion initiated by the recombinant tissue plasminogen activator (rtPA). By contrast, the intranasal (i.n.) treatment allows drug delivery to the brain via both a dense i.n. vasculature and the olfactory/trigeminal nerve pathway. [44,45] Thus, the i.n. treatment may not be as dependent on the quality of cerebral circulation after ischemic injury. In this study, we explore the therapeutic potential of i.n. PNU treatment using a tMCAO in young adult rats and show that i.n. treatment significantly reduces both infarct volume and neurological deficits.

The mechanisms responsible for $\alpha 7$ -mediated neuroprotection involve Ca^{2+} -dependent ERK1/2-[46,16] and PI3K/Akt-dependent[47,48] intracellular signaling pathways. Both pathways can be activated downstream of Ca^{2+} /calmodulin-dependent kinase-II (CaMKII). [49,50,16] Because PNU only amplifies activation of $\alpha 7$ nAChRs, PNU is expected to amplify activation of these same intracellular pathways in neurons of the penumbra after focal ischemia. In this study, we use KN93, a potent inhibitor of CaMKII, to test the involvement of CaMKII in the effects of PNU after a MCAO.

Therefore, this study employs a tMCAO model of cerebral ischemic stroke in young adult rats to test the hypothesis that endogenous $\alpha 7$ -dependent brain protection is available after focal cerebral ischemia and can be augmented by i.n. PNU via a CaMKII-dependent mechanism to significantly reduce brain injury and neurological deficits.

Materials and Methods

Animals

Young adult male Sprague-Dawley (SD) rats (~280 g) were purchased from Charles River (Wilmington, MA, USA) and used in accordance with the Guide for the Care and Use of Laboratory Animals (NIH 865-23, Bethesda, MD, USA). All experimental protocols were approved by the UNTHSC Institutional Animal Care and Use Committee. The UNTHSC animal facility is AAALAC accredited.

Transient middle cerebral artery occlusion (tMCAO)

Our approach was to conduct tMCAO within a very narrow and confirmed window of experimental parameters to ensure stable ischemic insult and injury in each experiment. Once these parameters have been established and confirmed by cerebral blood flow (CBF) measurements (see Figure 1), the parameters were then kept constant in all subsequent experiments supported by intermittent CBF measurements. Specifically, we used only 275-290 g Sprague-Dawley rats purchased from Charles Rivers and accommodated in our animal facility for 7 days after arrival. To initiate tMCAO, only 19 mm 4-0 monofilament nylon suture size was used. These restrictions ensured stability of experimental parameters across groups and reproducibility of outcomes during and after tMCAO.

A transient MCAO was induced using a suture technique as previously described.[51] Animals were anesthetized with 4% isoflurane mixed with 67% N₂O +29% O₂, delivered by a mask. After a midline incision in the neck, the left common carotid artery (CCA) was exposed and dissected. A 19-mm, 4-0 monofilament nylon suture was inserted from the CCA into the left internal carotid artery to occlude the origin of left MCA. After occlusion, the thread was removed for reperfusion. The CCA was permanently ligated, and the wound was closed. Rectal temperature was maintained at ~37°C using a heating pad.

A total of 136 animals were used in MCAO experiments. Of these: 9 rats (i.e., 6.6 %) did not survive the surgery. This mortality factor is reflected by the differences in sample sizes of experimental groups. All animals subjected to MCAO have shown ischemic infarcts 24 hrs after MCAO. In all experiments, animals were randomly assigned to groups prior to group labeling and all data were reported. However, the allocation concealment was not used because only one researcher conducted all *in vivo* experiments and data analysis (the statistical analysis was conducted by a different researcher) thus, the study cannot be viewed as blinded.

Cerebral blood flow measurements

Rats were anesthetized with 4% isoflurane mixed with 67% N₂O +29% O₂, delivered by a mask. A skin incision (~1 cm long) was made in the central area of the shaved skull and a probe holder with a Laser-Doppler flowmeter probe (Periflux system 5000; Perimed, Stockholm, Sweden) was attached to the skull (-1 mm bregma; 5 mm medial-lateral) in the left hemisphere ipsilateral to MCAO using a superglue. Regional cerebral blood flow (rCBF) was recorded before and during CCA occlusion (CCAO), and then, during and after MCAO as a percent of the mean baseline value recorded over the last 5 min before CCAO. A successful MCAO was defined as an abrupt reduction in rCBF by >70% followed by a recovery to the flow level corresponding to CCAO (Figure 1).

Drugs

PNU-120596 was purchased from Selleck Chemicals (Houston, TX, USA). Methyllcaconitine (MLA) was purchased from Abcam Biochemicals (Cambridge, MA, USA). KN92/KN93 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Other chemicals were purchased from ThermoFischer Scientific (Waltham, MA, USA).

Solutions and drug administration

Intravenous (i.v.) PNU (1 mg/kg) significantly reduces brain injury and neurological deficits after tMCAO[2,3]. Because the proportion of injected drug volume absorbed in the intranasal (i.n.) cavity is uncertain as some of the drug may leak out of the nostrils or enter the gastrointestinal tract, the i.n. treatment may generate errors in dosing. To account for that potential loss of treatment, in this study, we used a higher predicted dose (10 mg/kg) for i.n. PNU administration as compared to i.v. 1 mg/kg PNU used previously.[3]

To make a 0.2-1 M stock solution, PNU was dissolved in dimethyl sulfoxide (DMSO). Then, a 10 μ l micropipette with a small tip was used to inject up to 60 μ l of the stock solution (i.e., PNU+DMSO) or DMSO alone (i.e., vehicle) in one or both nostrils of the animal over a 2 min period to achieve the final dose of 10 mg/kg PNU. A water-based MLA stock solution (20 mM) or water alone (i.e., vehicle) were injected subcutaneously 10 min after the onset of MCAO. The amount of DMSO injected in each animal did not exceed 0.5 ml/kg.

Intracerebroventricular administration of KN92/KN93—Anesthetized animals were implanted with an osmotic minipump (Alzet 1003D; Alza Corporation, CA, USA). The cannula was placed into the left lateral ventricle, 2.0 mm lateral to the midline, 1.0 mm posterior to Bregma and 4.0 mm ventral to the pial surface. KN92 or KN93 were dissolved in DMSO to 10 mM and diluted in artificial cerebrospinal fluid (ACSF) to achieve 20 μ M. Animals were infused intracerebroventricular for 24 hr with 1 μ l/h of KN93, KN92 or vehicle starting at 20 min prior to MCAO onset.

Focal pressure puffs of KN93 in acute brain slices—KN93 was dissolved in DMSO at 10 mM, and then, diluted in ACSF to achieve 20 μ M. To apply KN93 focally, a tip of application pipette similar to that used for patch-clamp recordings was positioned within 10 μ m from the recorded neuron. Prolong pressure puffs (12 s duration at 10 psi pressure) delivered KN93 focally to the recorded neurons and the effects of KN93 on the persistent levels of α 7 nAChR activity could be determined. Due to diffusion, the apparent concentration of KN93 that the recorded neuron is exposed to during a pressure puff may be somewhat lower than the original concentration (i.e., 20 μ M) present in the application pipette. Thus, the application parameters used in this study (i.e., 12 s puff duration; 10 psi pressure; 10 μ m pipette distance from the recorded neuron) have been optimized in our earlier study[52] to eliminate the drug concentration drop during each pressure puff.

Infarct Volume Measurements

Anesthetized animals were euthanized by decapitation 24 hrs after MCAO. Brains were removed and coronal sections (2 mm thickness) immersed in 2% 2,3,5-triphenyltetrazolium chloride in saline for 20 min at 37°C, then fixed for 2 hrs in 4% paraformaldehyde. The infarct and contralateral hemisphere areas were measured using the Image-J software. Section areas were multiplied by the distance between sections to obtain the respective volumes. The infarct volume was calculated as a percentage of the contralateral slice volume to account for a possible edema in the ischemic hemisphere.

Neurobehavioral testing

Animals were trained prior to MCAO (training period: 3 days, 3 trials daily) and deficits were assessed 24 hrs thereafter as described in detail previously.[3] The order of testing (Bederson→cylinder→ladder rung walking) was always the same to keep the testing conditions identical for all animals.

Bederson test—Bederson score was used to assess the neurological deficit using a four-level scale: 0, normal; 1, forelimb flexion; 2, decreased resistance to lateral push; 3, circling.

Cylinder Test—Forelimb use was analyzed by observing the rat's movements over 3-minute intervals in a transparent, 18-cm-wide, 30-cm-high poly-methyl-methacrylate cylinder. A mirror behind the cylinder made it possible to observe and record forelimb movements when the rat was facing away from the examiner. After an episode of rearing and wall exploration, a landing was scored for the first limb to contact the wall or for both limbs if they made simultaneous contact. Percentage use of the impaired limb was calculated.

Ladder rung walking test—The ladder rung walking test is sensitive for quantifying skilled locomotion. The degree of motor dysfunction after MCAO was measured by counting the number of foot-faults of the impaired limbs per round.[3] Baseline and post-operative testing sessions consisted of three traverses across the ladder. An error was scored for any foot slip or misstep. The number of errors of the affected forelimb and hindlimb in each trial was counted. The mean number of errors in three traverses was calculated.

Measurements of PNU in blood and brain samples using mass spectrometry (MS)

Young adult male Sprague-Dawley rats (~280 g) were subjected to i.n. PNU (10 mg/kg). Animals were then anesthetized with 4% isoflurane mixed with 67% N₂O +29% O₂, delivered by a mask 3 hours after PNU injection and blood samples were collected intracardially. Animals were then euthanized by decapitation; brain tissues from the motor-somatosensory cortical areas and the corresponding striatal regions were rapidly collected. All samples were immediately flash frozen in liquid nitrogen and stored at -80°C at UNTHSC (Fort Worth, TX, USA). Samples were then shipped on dry ice overnight to Carbon Dynamics Institute, LLC (Sherman, IL, USA) for MS determinations. Subsamples were macerated with methanol for 3 min and the resultant slurry was centrifuged at 4°C for 15 min at 15 000× *g*. Blood samples were centrifuged at 4°C for 15 min at 19 000× *g*. The resultant supernatant for both preparations was further purified using a mixed-mode polymeric exchange solid phase extraction (SPE). The eluate was lyophilized and reconstituted in the initial mobile phase. PNU was analyzed by a one microliter injection of each sample aliquot into a Waters 2795 Alliance equipped with a XBridge BEH130 C₁₈ 2.1 mm × 150 mm, 3.5 μm particulate column (110 Å) at a flow rate of 0.150 mL·min⁻¹; a binary mobile phase gradient at 50:50 (2.5%) A : B in 20 min (mobile phase A = 0.01% formic acid; mobile phase B = acetonitrile) until proper peak shape, separation and reduction of interferences were obtained (Figure 2A-B). Waters Quattro Ultima triple stage quadrupole mass spectrometer equipped with an electrospray ionization source was calibrated with methionine-arginine-phenylalanine-alanine peptide for both the single and double charge state (*m/z* 524.2 and 262.6, respectively) to provide a 0.1 amu mass accuracy for each [M +

$H]^+$ parent ion (m_p^{+}) (Figure 2A-C). The m_p^{+} ion 312 from Q1 was passed through a collision chamber (Q2), operating in radio-frequency-only mode (25 V), and focused for subsequent ionization as a consequence of the collision of the rapidly moving m_p^{+} with an inert gas (Ar) at ~ 1.8 mTorr to produce the unique product fragmentation spectrum that was subsequently scanned through a third mass filter (Q3) where selected daughter ions (m_d^{+}) were collected in multiple resonance monitoring (transitions $312 > 173, 188$ and 158) (Figure 2D). A total of 6 animals were used for evaluation of PNU levels in blood and brain tissue samples.

Acute hypothalamic slices: tissue preparation and whole-cell patch-clamp recordings

Three-four coronal whole-brain slices (260 μ m thickness) containing the hypothalamic tuberomammillary (TM) nuclei were cut in a sucrose-rich solution at 3°C using a 7000smz-2 vibrating microtome (Campden Instruments Ltd., Lafayette, IN, USA). The sucrose-rich solution was of the following composition (in mM): 250 sucrose, 3 KCl, 1.23 NaH_2PO_4 , 5 $MgCl_2$, 0.5 $CaCl_2$, 26 $NaHCO_3$ and 10 glucose (pH 7.4, when bubbled with carbogen, i.e., 95 % O_2 and 5% CO_2). The brain slices were then transferred to a temporary storage chamber where they were maintained for ~ 1 hr at 30°C and then, up to 8 hrs at room temperature in an oxygenated ACSF of the following composition (in mM): 125 NaCl, 3 KCl, 1.23 NaH_2PO_4 , 1 $MgCl_2$, 2 $CaCl_2$, 26 $NaHCO_3$ and 10 glucose (pH 7.4, when bubbled with carbogen).

For patch-clamp recordings, slices were transferred to a recording chamber perfused with ACSF at room temperature. Recordings were made using a MultiClamp-700B amplifier and Digidata-1440A A/D converter (Molecular Devices, Sunnyvale, CA, USA). Data were sampled at 10 kHz and filtered at 2 kHz. Recording pipettes were pulled using a Sutter P-97 puller (Sutter Instruments, Novato, CA, USA). The pipette resistance was 4-6 MO. After formation of a giga-seal (> 2 G Ω), the whole-cell configuration was established. Choline and PNU-120596 were added to ACSF and KN93 was pressure-applied (at 5–8 psi) via a picospritzer (Parker Hannifin, Cleveland, OH, USA) using pipettes identical to those used for recordings. The application pipette tips were positioned ~ 10 μ m away from the recorded neuron. Recordings were conducted at room temperature. The membrane voltage was clamped at -60 mV in all experiments. The extracellular solution was identical to ACSF that was used for preparation and storage of slices. The recording electrodes were filled with an intracellular solution of the following composition (in mM): 140 K-gluconate, 1 NaCl, 2 $MgCl_2$, 2 Mg-ATP, 0.3 Na-GTP, 10 HEPES (pH 7.4 adjusted with KOH). The membrane voltage was not corrected for the liquid junction potential: $V_{LJ} \sim 16$ mV. A custom-made perfusion pump was used to perfuse slices in the recording chamber at a rate of 1.5 ml/min.

Statistical Analysis

Data obtained from behavioral assays (i.e., based on a scoring system) were analyzed using two-tailed non-parametric Kruskal-Wallis or Mann-Whitney tests. Statistical significance of continuous data (i.e., infarct volume) was defined by a one-way ANOVA followed by individual F-test comparisons among groups or a two-tailed Student's test. The alpha level was set at 0.05. The results are presented as mean $\pm$ S.E.M.

Results

Evaluation of PNU levels in blood and brain tissue samples

Samples of blood and brain tissues were collected 3 hrs after i.n. 10 mg/kg PNU injection and analyzed for PNU content using mass-spectrometry (see *Materials and Methods*). The analysis demonstrated the presence of PNU in all samples at the following concentrations (n=6): 2.2 ± 0.6 ng/ml (blood), 10.8 ± 2.8 ng/g (cortex) and 17.4 ± 5.5 ng/g (striatum). The statistical significance of differences in the levels of PNU in blood, cortex and striatum were evaluated using a one-way ANOVA with individual F-test comparisons. This analysis indicated that the concentration of PNU in samples significantly depends on the sample type: $F(2,15)=4.551$, $p=0.0285$, $n=6$. The corresponding post-tests comparisons detected the following levels of significance among PNU concentrations in sample groups (n=6 per group): cortex vs. striatum ($t=1.304$, $df=15$, $p=0.2120$); blood vs. cortex ($t=1.705$, $df=15$, $p=0.1089$); and blood vs. striatum ($t=3.008$, $df=15$, $p=0.0088$). Thus, cortical and striatal brain tissues appear to accumulate PNU equally. However, the concentration of PNU in striatal brain tissues was significantly greater than that found in blood which is consistent with our previous results.[2]

Endogenous $\alpha 7$ -dependent protection after tMCAO

IV. PNU treatments after a 90 min tMCAO have been demonstrated to significantly reduce infarct volume and neurological deficits[2,3] and these effects of PNU have been proposed to arise from the augmented protective action of $\alpha 7$ nAChRs activated by extracellular choline elevated focally by ischemic injury.[6,2] However, the presence of endogenous protection in untreated animals and its limitations have not been directly detected. To identify this endogenous protective action in the absence of PNU, we used s.c. 10 mg/kg MLA, a selective $\alpha 7$ antagonist. Animals were randomly selected, subjected to a 90 min tMCAO and treated either with s.c. saline or s.c. MLA 10 min after tMCAO onset. Infarct volume and neurological deficits were determined 24 hrs after tMCAO.

MLA failed to significantly increase infarct volume after a 90 min tMCAO (unpaired, two-tail Student's t-test, $t=0.3572$, $df=12$, $p=0.7271$, 95% CI: -10.75, 7.72, $n=6-8$; Figure 3A-B) suggesting that $\alpha 7$ activation does not produce significant protective action in the absence of PNU in this experimental paradigm. These results also suggested that ischemic brain injury resulting from a 90 min tMCAO is too extensive (~45%; Figure 3A-B) for endogenous protection and thus, the use of PNU or other PNU-like $\alpha 7$ -PAMs is absolutely required to achieve significant $\alpha 7$ -dependent protection in these settings. To test whether a less severe injury is more receptive to endogenous protection, animals were subjected to a 60 min tMCAO and treated with s.c. saline or s.c. MLA 10 min after tMCAO onset. Infarct volume and neurological deficits were determined 24 hrs after tMCAO. Reducing the duration of tMCAO from 90 to 60 min resulted in a ~50% reduction of infarct volume (~22% vs. ~45%; open columns in Figures 3C-D vs. Figures 3A-B). MLA significantly increased infarct volume after a 60 min tMCAO from 20% to 35% (unpaired, two-tail Student's t-test, $t=2.272$, $df=14$, $p=0.0393$, 95% CI: 0.7724, 26.72, $n=7-9$; Figure 3C-D), an increase of ~75%, supporting our hypothesis that endogenous $\alpha 7$ -dependent protection is more effective after a less severe ischemic injury. The results of behavioral tests were consistent

with these data: MLA failed to produce significant neurological deficits after a 90 min tMCAO (unpaired, two-tailed Mann-Whitney, $n=11-12$): Bederson ($p=0.3556$, 95% CI: 0.0, 1.0); cylinder ($p=0.6127$, 95% CI: -10.0, 2.5) and limb placing ($p=0.4478$, 95% CI: -1.0, 0.0) (Figure 4A-C). By contrast, significant neurological deficits after MLA were detected in two tests after a 60 min tMCAO (unpaired, two-tailed Mann-Whitney, $n=11-12$): Bederson ($p=0.0427$, 95% CI: 0.0, 2.0) and cylinder ($p=0.0227$, 95% CI: -45.0, 0.0; Figure 4D-E). The remaining test (limb placing) conducted after a 60 min tMCAO failed to detect significant differences between MLA-treated and control groups: $p=0.5940$, 95% CI: -7.0, 2.0 (Figure 4F). Therefore, these results revealed significant endogenous $\alpha 7$ -dependent brain protection after a 60 min tMCAO and suggested that this protective action of $\alpha 7$ nAChRs does not extend to more severe injuries modeled here by a 90 min tMCAO.

Protective action of intranasal (i.n.) PNU

I.N. drug delivery utilizes both the vast in. vasculature and the olfactory/trigeminal nerves. [44,45] Thus, we expected to detect a high therapeutic utility of i.n. PNU treatment after tMCAO. To test this hypothesis, animals were subjected to a 90 min tMCAO and treated with either i.n. vehicle (i.e., DMSO) or i.n. PNU (10 mg/kg) 30 min after tMCAO onset with or without MLA pre-treatment (i.e., PNU $\pm$ MLA groups). To account for a potential loss of therapeutic action due to a leak of PNU out of the animals' nostrils or entering the gastrointestinal tract, the i.n. PNU dose was increased 10-fold as compared to the dose used in our previous study utilizing intravenous injections.[3] Infarct volume and neurological deficits were determined 24 hrs after tMCAO. I.N. PNU significantly reduced infarct volume (one-way ANOVA with individual F-test comparisons; $F(2,12)=9.730$, $p=0.0031$, $n=5$; *squares vs. circles*, Figure 5A-B) and neurological deficits (Kruskal-Wallis with Dunn's multiple comparisons test; Figure 5C-E) in control ($n=10$) vs. PNU-treated ($n=13$) groups in the following behavioral tests: Bederson ($H=23.00$, $p<0.0001$; Figure 5C); cylinder ($H=20.94$, $p<0.0001$; Figure 5D) and limb placing ($H=25.85$, $p<0.0001$; Figure 5E). The corresponding post-tests multiple comparison tests detected the following levels of significance among vehicle-and PNU-treated groups: infarct volume ($t=3.889$, $df=12$, $p=0.0022$), Bederson ($p=0.0002$); cylinder ($p=0.0036$) and limb placing ($p<0.0001$). These effects of PNU were reversed by MLA (s.c. 10 mg/kg; $n=12$) injected 10 min after tMCAO onset (*triangles vs. squares*) as evidenced from significant effects produced by MLA (i.e., PNU vs. PNU+MLA groups) in all tests: i.e., infarct volume ($t=3.748$, $df=12$, $p=0.0028$); Bederson ($p=0.0001$); cylinder ($p<0.0001$); and limb placing ($p<0.0001$). Significant differences were not detected between control and MLA-treated groups in all tests ($p>0.05$, *circles vs. triangles*; Figure 5B-E). These results support the high therapeutic utility of i.n. PNU after a 90 min tMCAO and confirm the involvement of $\alpha 7$ nAChRs.

KN93 inhibits protective effects of i.n. PNU

Because PNU only amplifies $\alpha 7$ activation by agonists,[41] we hypothesize that protective action by PNU after tMCAO arises from amplified CaMKII-dependent signaling pathways downstream of $\alpha 7$ activation.[49,50,16] To test this hypothesis, we used KN93, a potent inhibitor of CaMKII and its phosphorylating activity, that prevents association of calmodulin with CaMK without any effects on PKA, PKC and Ca^{2+} -phosphodiesterase.[53] Intracerebroventricular (i.c.v.) infusion of KN93 completely eliminated the effects of i.n.

PNU after a 90 min tMCAO, as evidenced by statistically significant changes in infarct volume (one-way ANOVA with individual F-test comparisons; $F(2,14)=5.522$, $p=0.0171$, $n=5-7$; Figure 6A-B) and neurological deficits (Kruskal-Wallis with Dunn's multiple comparisons test; Figure 6C-E) among PNU-, PNU+KN92 and PNU+KN93-treated groups ($n=8-9$) in the following behavioral tests: Bederson ($H=8.798$, $p=0.0123$; Figure 6C); cylinder ($H=13.27$, $p=0.0013$; Figure 6D) and limb placing ($H=11.81$, $p=0.0027$; Figure 6E). The corresponding post-tests multiple comparison tests detected the following levels of significance among PNU- and PNU+KN93-treated groups (*circles vs. squares*): infarct volume ($t=2.943$, $df=14$, $p=0.0107$), Bederson ($p<0.05$), cylinder ($p<0.05$) and limb placing ($p<0.05$). A similar i.c.v. treatment with KN92, an inactive analogue of KN93, failed to significantly alter the effects of PNU in all tests ($p>0.05$; *triangles vs. circles*, Figure 6B-E). Accordingly, significant differences were detected between PNU+KN92 and PNU+KN93 groups in all tests ($p<0.05$; *triangles vs. squares*, Figure 6B-E).

A statistically significant increase in infarct volume was detected after i.c.v. KN93 treatment alone (i.e., without PNU) (unpaired, two-tailed Student's t-test; $t=2.373$, $df=9$, $p=0.0417$, 95% CI: 0.4539, 18.97, $n=5-6$; Figure 6F-H) supporting the presence of endogenous $\alpha 7$ -dependent protective action after tMCAO. These data support the requirement for CaMKII activity downstream of $\alpha 7$ activation in generating the therapeutic efficacy of both endogenous $\alpha 7$ -dependent brain protection and PNU after a 90 min tMCAO.

KN93 does not directly block $\alpha 7$ nAChRs

To eliminate a possibility that KN93 directly blocks $\alpha 7$ nAChRs, we conducted electrophysiological patch-clamp recordings of $\alpha 7$ nAChR-mediated responses using hypothalamic tuberomammillary (TM) neurons in acute brain slices. TM neurons act as a unique reliable source of native functional homomeric $\alpha 7$ nAChRs.[31,32,54,27] Acute brain slices containing the TM nuclei were perfused with 1 μ M PNU and 20 μ M choline to model conditions and persistent activation of $\alpha 7$ nAChRs that occurs in the ischemic peri-infarct areas in our *in vivo* experiments after tMCAO and i.n. PNU treatment.[2,37] Prior to patch-clamp recordings, the acute brain slices were pre-incubated in 1 μ M PNU for at least 50 min to equilibrate the concentration of PNU within the slice as we have justified previously[27,43]. Choline (20 μ M) added to the artificial cerebrospinal fluid (ACSF) produced a clearly detectable persistent whole-cell current upon its entrance in the recording chamber (Figure 7A). This choline-mediated current stabilized shortly after initiation, as we discussed previously.[27,43] KN93 (20 μ M) was dissolved in ACSF containing 1 μ M PNU +20 μ M choline and administered focally to the recorded neuron using pressure application pipette identical to that used for patch-clamp recordings. The puff pipette was positioned within 10 μ m from the recorded neuron and connected to a pico-spritzer. Prolonged pressure puffs (12 s duration at 10 psi pressure) of KN93 (gray box above current traces) did not inhibit the level of persistent $\alpha 7$ nAChR activation (Figure 7B). On the contrary, a small but significant increase in the current levels was detected (Figure 7C). Data were recorded from $n=6$ TM neurons obtained from $m=2$ preparations/rats. The level of activation was quantified by measuring the mean current over two time windows of equal durations: i.e., T1 (12 s prior to KN93) and T2 (12 s during KN93) (Figure 7B). These experiments determined that 20 μ M KN93 does not directly inhibit $\alpha 7$ nAChR activity mediated by 20 μ M choline in the

presence of 1 μ M PNU. The concentration of KN93 selected for these experiments (i.e., 20 μ M) was similar to that used in our i.c.v. injections.

Discussion

This study used selective pharmacological agents and a tMCAO model of ischemic stroke in young adult rats to detect endogenous brain protection that requires activation of $\alpha 7$ nAChRs during the acute post-tMCAO phase, i.e., in the first 24 hrs after tMCAO. The therapeutic utility of this protection was found to be limited to less severe ischemic injuries modeled in this study by a 60 min tMCAO, and did not appear to extend to more severe injuries modeled by a 90 min tMCAO (Figures 3-4). An immediate implication of these results is that truly unprotected animals may not exist, at least in the first 24 hrs after tMCAO, because endogenous $\alpha 7$ -dependent mechanisms protect both brain tissues and neurological functions even in untreated animals subjected to tMCAO. These results also suggest that ischemic brain injury resulting from a 90 min tMCAO is too extensive (~45%; Figure 3) and resistant to endogenous $\alpha 7$ -dependent protection. Thus, the use of $\alpha 7$ -PAMs is absolutely required to achieve significant $\alpha 7$ -dependent protection in these or similar settings (Figure 5).

Our experimental protocol employed a 24 hr delay between tMCAO and behavioral/histological assays. A potential limitation of this approach is that ischemic brain injury may not be fully matured 24 hrs after tMCAO and thus, the long-term (e.g., days, weeks) efficacy of PNU treatment cannot be reliably predicted. However, we view the initial 24 hrs after stroke to be especially critical because a timely administered PNU treatment that reduces brain injury in the first few hours after stroke may impede stroke maturation and help reduce long-term post-stroke sequelae including edema, synaptic degeneration and excessive inflammation, thus, may improve clinical outcomes. The long-term therapeutic efficacy of PNU-like $\alpha 7$ -PAMs is being investigated in our ongoing research.

The rational basis for the therapeutic use of PNU or PNU-like $\alpha 7$ -PAMs as a post-stroke treatment in mammals is tripartite[6,55,4] and arises from: 1) the potent neuroprotective effects of $\alpha 7$ nAChR activation;[15,16,2,3,17,56,12,18-23] 2) the presence of endogenous extracellular choline, elevated by ischemic injury;[37,39,36,40,6] and 3) the ubiquitous expression of $\alpha 7$ nAChRs in the mammalian brain, including regions highly vulnerable to ischemia.[8-10] Because PNU does not directly activate $\alpha 7$ nAChRs, but only amplifies $\alpha 7$ activation [27] by injury-elevated choline near the site and time of the injury,[6,4] the challenge of a timely focal delivery of PNU treatment to the ischemic penumbra is naturally resolved: while systemically applied PNU is somewhat homogeneously distributed throughout the body by circulation, its therapeutic effects would take place mostly, or even exclusively, in the brain areas with elevated extracellular choline,[40,37] i.e., exactly where and when it is most needed: in the ischemic penumbra, post-injury. Therefore, the high spatiotemporal precision of $\alpha 7$ -PAM therapies after ischemic stroke is an important benefit of this approach.

Because $\alpha 7$ nAChRs and phosphatidylcholine-based cell membranes are common in the mammalian brain, including rodents and humans,[30,57] the endogenous $\alpha 7$ -dependent

brain protection may act as an evolutionarily-shaped common mammalian mechanism that can be significantly amplified by PNU-like $\alpha 7$ -PAMs. Thus, there is a rational basis to expect that the therapeutic utility of PNU revealed in our studies in young adult rats will extend to human brain. Furthermore, in addition to anti-ischemic action, PNU-like $\alpha 7$ -PAMs exhibit pro-cognitive[34] and anti-nociceptive[33] properties by the same mechanism: augmenting the endogenous $\alpha 7$ -dependent cholinergic tone.

While in our previous studies PNU was administered either i.v. or s.c.,[2,3,55], in this study, we explored the i.n. route. One potential advantage of i.n. treatment is that it allows drugs be delivered to the brain via both circulation (because of a dense i.n. vasculature) and direct transport (because of a direct olfactory/trigeminal nerve pathway). In ischemic stroke, a fully functional cerebral circulation in the peri-infarct areas is unlikely even after rtPA treatment and thus, the dual delivery pathway provided by i.n. treatment may yield additional benefits and enhance treatment efficacy. One disadvantage of i.n. treatments is potential errors in dosing and thus, a potential need to use higher drug concentrations because the proportion of injected drug volume absorbed in the i.n. cavity is uncertain as some of the drug may leak out of the nostrils or enter the gastrointestinal tract. To account for that potential loss of treatment, we used a higher dose (10 mg/kg) for i.n. PNU administration in this study as compared to 1 mg/kg i.v. PNU used previously.[3] Nevertheless, our data suggest a high therapeutic utility for i.n. PNU treatment that is worth further consideration.

The levels of PNU found in blood (~2 ng/ml), cortical (~11 ng/g) and striatal (~17 ng/g) samples collected 3 hrs after i.n. injection at 10 mg/kg were lower than those found in blood (~63 ng/ml), cortical (~158 ng/g) and striatal (~150 ng/g) samples collected 3 hrs after s.c. injection at 30 mg/kg and reported previously.[2] These differences may reflect lower doses and/or lower bioavailability of i.n. PNU as well as delays in PNU delivery to blood and brain tissues after i.n. injection as compared to s.c. injection. Nevertheless, the therapeutic efficacy of i.n. 10 mg/kg PNU (Figure 5A-B; this study) was found to be very similar to that of i.v. 1 mg/kg PNU (Figure 5D-F; [2]) suggesting that i.n. PNU administration presents a compelling strategy.

The results of this study support our hypothesis that the mechanism underlying therapeutic effects of PNU after focal cerebral ischemia involves a desensitization reversal and enhanced activation of $\alpha 7$ nAChRs[41,27,43] in the ischemic penumbra and peri-infarct areas leading to activation of CaMKII-dependent intracellular signaling pathways and therapeutic efficacy (Figure 6). These mechanisms are directly associated with and downstream of $\alpha 7$ nAChR activation as proposed previously for the action of $\alpha 7$ agonists.[46,16,47,48] Because PNU, as a typical $\alpha 7$ -PAM, is highly selective and does not directly activate any receptors, but simply enhances activation of $\alpha 7$ nAChRs by nicotinic agonists,[41,6,27,43] these results are consistent with the notion that the effects of PNU are directly derived from enhanced activation of $\alpha 7$ nAChRs and $\alpha 7$ -dependent intracellular pathways. The finding that KN93 significantly increases infarct volume without PNU treatment (Figure 6F-H) supports the presence of endogenous CaMKII-dependent protection after MCAO that may include an $\alpha 7$ -dependent component (Figure 5). The possibility that KN93 reversed the effects of PNU by a direct inhibition of $\alpha 7$ nAChRs was eliminated by electrophysiological experiments using $\alpha 7$ -expressing TM neurons in acute slices[54] where direct inhibitory effects of KN93 on

persistent $\alpha 7$ -mediated currents were not detected (Figure 7). These results are consistent with the predicted inhibition of CaMKII by KN93 and a reduced neuroprotective efficacy of PNU in the presence of KN93.

By re-activating desensitized $\alpha 7$ nAChRs,[41] PNU augments and prolongs endogenous $\alpha 7$ -dependent cholinergic tone in the ischemic penumbra[6] significantly reducing brain injury and neurological deficits in the first 24 hrs after tMCAO (Figure 5). This ability of PNU to re-activate desensitized $\alpha 7$ nAChRs[41] is critical because the extracellular concentration of choline in the ischemic core/penumbra is elevated manifold within the first few hours after MCAO onset[37] and as a result, a certain portion of $\alpha 7$ nAChRs in the ischemic penumbra is expected to be desensitized ($IC_{50} \sim 40 \mu M$)[28] and unable to fully participate in protective action.[37]

Because the normal physiological level of cerebral extracellular choline is low (i.e., $<10 \mu M$) [29,24,25] and sub-threshold for $\alpha 7$ activation,[28] it is unlikely that extracellular choline is protective in the absence of injury or $\alpha 7$ -PAMs. Thus, the finding that MLA significantly increases infarct volume and neurological deficits after tMCAO suggests that endogenous $\alpha 7$ -dependent brain protection is indeed produced by extracellular choline elevated by tMCAO[37] and thus, is a focal, not global, phenomenon. However, the same low physiological levels of choline in the absence of injury could pre-condition brain tissues in the presence of PNU and thus, enhance neuronal resistance to injury, as we reported previously in oxygen-glucose deprivation (OGD) experiments in acute hippocampal slices. [2] In those experiments, preincubation of slices in 20-200 μM choline plus 1 μM PNU significantly delayed terminal anoxic depolarization of CA1 pyramidal neurons, thus, enhanced their resistance to OGD.[2] Therefore, in addition to amplifying the effects of injury-elevated extracellular choline focally in the ischemic penumbra post-MCAO, $\alpha 7$ -PAMs may also produce a global, $\alpha 7$ -dependent (but injury-independent) protective pre-conditioning among $\alpha 7$ -expressing neurons resulting from synergistic action of $\alpha 7$ -PAMs and normal (i.e., low; $<10 \mu M$) physiological levels of choline. This global pre-conditioning would remain undetected in the absence of injury (e.g., tMCAO) or insult (e.g., OGD), but could be revealed by experimental insults that do not elevate extracellular choline: e.g., OGD in acute slices continuously perfused with ACSF.[2] The benefits from PNU-induced pre-conditioning appear to be short-lived with the rate matching the rate of PNU clearance (~ 8 hrs[42]) because s.c. PNU (which is effective when injected 3 hrs prior to tMCAO) becomes ineffective when injected 24 hrs prior to tMCAO.[2] Therefore, PNU appears to produce both a *focal* protective action in the ischemic penumbra where extracellular choline is elevated by ischemic injury; and a *global* protective pre-conditioning in brain areas unaffected by MCAO where extracellular choline remains sub-threshold for $\alpha 7$ activation in the absence of $\alpha 7$ -PAMs.[39,29]

While PNU treatment is effective after a 90 min tMCAO, the contributing protective pathways are not fully understood. In fact, because $\alpha 7$ nAChRs are ubiquitously expressed in neuronal and non-neuronal tissues, the therapeutic efficacy of $\alpha 7$ -PAMs may result from multiple and relatively independent components. For example, we have shown previously that physiologically-relevant concentrations of choline (20-200 μM) in the presence of 1 μM PNU produced neuroprotection in an OGD model of cerebral ischemia in acute hippocampal

slices[2]. These data supported the neuroprotective component of $\alpha 7$ -PAM action. $\alpha 7$ -PAMs may also enhance activation of $\alpha 7$ nAChRs expressed in the autonomic neuronal circuitry which provides neurogenic control over vascular tone (e.g., adrenergic, nitrgenic)[58,59] and thus, may cause elevation of the collateral blood supply within the ischemic penumbra. Because $\alpha 7$ nAChRs are expressed in glial and immune cells,[60,61,55,4,7] $\alpha 7$ -PAMs may contribute to brain protection by augmenting endogenous $\alpha 7$ -dependent cholinergic anti-inflammatory mechanisms activated by injury.[12,13,62,63,11,23,55,60,61,64,4,7] On the other hand, excessive prolonged activation of $\alpha 7$ nAChRs by high concentrations of $\alpha 7$ agents can be toxic for biological cells as demonstrated and discussed previously.[65-70] Thus, it is essential for future *ex vivo* and *in vitro* studies to employ physiologically- and clinically-relevant drug concentrations and treatment conditions available in the literature. [42,2,37,25,24,68] The use of clinically-relevant experimental conditions in *ex vivo* and *in vitro* studies should not be a matter of preference because in the absence of clinically-effective therapies, the continuing suffering of stroke victims and the associated financial burden demand prompt effective solutions.

In conclusion, although the physiological role of $\alpha 7$ nAChRs in the central nervous system is largely unknown, the results of this study suggest that the therapeutic activation of $\alpha 7$ nAChRs in the penumbra after focal cerebral ischemia serves as an important physiological responsibility of these ubiquitous receptors and can be significantly augmented by $\alpha 7$ -PAMs; thus, may hold an attractive translational potential.

Clinical Perspectives

This study used a transient focal cerebral ischemia model of ischemic stroke to detect the early (i.e., the first 24 hrs post-tMCAO) endogenous choline-/ $\alpha 7$ -CaMKII-dependent mechanisms of brain self-protection that can be augmented by positive allosteric modulators of $\alpha 7$ nAChRs, such as PNU120596. Because PNU120596 only amplifies $\alpha 7$ activation by injury-elevated extracellular choline in the ischemic peri-infarct region, the challenge of a timely focal delivery of PNU120596 treatment to the ischemic penumbra is naturally resolved: while systemically applied PNU120596 is distributed throughout the body by circulation, its therapeutic effects take place mostly, or even exclusively, in the brain areas with elevated extracellular choline, i.e., exactly where and when it is most needed: in the ischemic penumbra, post-injury. Therefore, the high spatiotemporal precision of $\alpha 7$ -PAM therapies at the early stage after ischemic stroke is an important benefit of this approach. Because $\alpha 7$ nAChRs and phosphatidylcholine-based cell membranes are common in the mammalian brain, including humans, the endogenous choline-/ $\alpha 7$ -dependent protection may serve as an evolutionarily-shaped common mammalian brain protective mechanism that can be significantly amplified by $\alpha 7$ -PAMs. Thus, there is a rational basis to expect that the therapeutic utility of acute $\alpha 7$ -PAM treatment will naturally extend to humans. Here, we discuss an unconventional approach to managing acute brain injury and neurological deficits at the early stage (i.e., the first 24 hrs) after cerebral ischemia. This approach can become a starting point for developing clinically efficacious $\alpha 7$ -PAM-based therapies that may enable health care providers to overcome current limitations associated with the lack of effective treatments after stroke.

Acknowledgments

This study was supported by the NIH grant DK082625 and a grant from the Rainwater Charitable Foundation to VU.

References

1. Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ. International Citicoline Trial on acute Stroke trial i. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). *Lancet*. 2012; 380(9839):349–357. DOI: 10.1016/S0140-6736(12)60813-7 [PubMed: 22691567]
2. Kalappa BI, Sun F, Johnson SR, Jin K, Uteshev VV. A positive allosteric modulator of $\alpha 7$ nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia. *Br J Pharmacol*. 2013; 169(8):1862–1878. DOI: 10.1111/bph.12247 [PubMed: 23713819]
3. Sun F, Jin K, Uteshev VV. A Type-II Positive Allosteric Modulator of $\alpha 7$ nAChRs Reduces Brain Injury and Improves Neurological Function after Focal Cerebral Ischemia in Rats. *PLoS one*. 2013; 8(8):e73581.doi: 10.1371/journal.pone.0073581 [PubMed: 23951360]
4. Uteshev VV. Allosteric modulation of nicotinic acetylcholine receptors: the concept and therapeutic trends. *Curr Pharm Des*. 2016; doi: 10.2174/1381612822666160201115341
5. Hays SA, Rennaker RL, Kilgard MP. Targeting plasticity with vagus nerve stimulation to treat neurological disease. *Prog Brain Res*. 2013; 207:275–299. DOI: 10.1016/B978-0-444-63327-9.00010-2 [PubMed: 24309259]
6. Uteshev VV. The therapeutic promise of positive allosteric modulation of nicotinic receptors. *Eur J Pharmacol*. 2014; 727:181–185. DOI: 10.1016/j.ejphar.2014.01.072 [PubMed: 24530419]
7. Uteshev VV, Tenovuo O, Gaidhani N. The cholinergic potential, the vagus nerve and challenges in treatment of traumatic brain injury. *Curr Pharm Des*. 2016; doi: 10.2174/1381612822666160127111630
8. Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, Sullivan B, Demasters BK, Freedman R, Leonard S. Comparison of the regional expression of nicotinic acetylcholine receptor $\alpha 7$ mRNA and [125I]- α -bungarotoxin binding in human postmortem brain. *J Comp Neurol*. 1997; 387(3):385–398. DOI: 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X [PubMed: 9335422]
9. Whiteaker P, Davies AR, Marks MJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Collins AC, Wonnacott S. An autoradiographic study of the distribution of binding sites for the novel $\alpha 7$ -selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. *Eur J Neurosci*. 1999; 11(8):2689–2696. DOI: 10.1046/j.1460-9568.1999.00685.x [PubMed: 10457165]
10. Woodruff TM, Thundiyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. *Mol Neurodegener*. 2011; 6(1):11.doi: 10.1186/1750-1326-6-11 [PubMed: 21266064]
11. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation. *Nature*. 2003; 421(6921):384–388. DOI: 10.1038/nature01339 [PubMed: 12508119]
12. Parada E, Egea J, Buendia I, Negrodo P, Cunha AC, Cardoso S, Soares MP, Lopez MG. The Microglial $\alpha 7$ -Acetylcholine Nicotinic Receptor Is a Key Element in Promoting Neuroprotection by Inducing Heme Oxygenase-1 via Nuclear Factor Erythroid-2-Related Factor 2. *Antioxid Redox Signal*. 2013; doi: 10.1089/ars.2012.4671
13. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98(7):4148–4153. DOI: 10.1073/pnas.071540198 [PubMed: 11259680]
14. Kalappa BI, Feng L, Kem WR, Gusev AG, Uteshev VV. Mechanisms of facilitation of synaptic glutamate release by nicotinic agonists in the nucleus of the solitary tract. *Am J Physiol Cell Physiol*. 2011; 301(2):C347–361. DOI: 10.1152/ajpcell.00473.2010 [PubMed: 21613611]

15. Del Barrio L, Martin-de-Saavedra MD, Romero A, Parada E, Egea J, Avila J, McIntosh JM, Wonnacott S, Lopez MG. Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by $\alpha 7$ and $\beta 2^*$ nicotinic stimulation. *Toxicol Sci.* 2011; 123(1):193–205. DOI: 10.1093/toxsci/kfr163 [PubMed: 21715663]
16. Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca^{2+} FASEB J. 2011; 25(8):2563–2573. DOI: 10.1096/fj.11-182824 [PubMed: 21507900]
17. Egea J, Rosa AO, Sobrado M, Gandia L, Lopez MG, Garcia AG. Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in $\alpha 7$ nicotinic receptor knockout mice. *Neuroscience.* 2007; 145(3):866–872. DOI: 10.1016/j.neuroscience.2006.12.036 [PubMed: 17291692]
18. Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. *Brain Res.* 1994; 644(2):181–187. doi:0006-8993(94)91678-0. [PubMed: 7519524]
19. Shimohama S, Greenwald DL, Shafroon DH, Akaike A, Maeda T, Kaneko S, Kimura J, Simpkins CE, Day AL, Meyer EM. Nicotinic $\alpha 7$ receptors protect against glutamate neurotoxicity and neuronal ischemic damage. *Brain Res.* 1998; 779:359–363. DOI: 10.1016/S0006-8993(97)00194-7 [PubMed: 9473725]
20. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. *Ann Neurol.* 1997; 42(2):159–163. DOI: 10.1002/ana.410420205 [PubMed: 9266724]
21. Li Y, Papke RL, He YJ, Millard WJ, Meyer EM. Characterization of the neuroprotective and toxic effects of $\alpha 7$ nicotinic receptor activation in PC12 cells. *Brain Res.* 1999; 830(2):218–225. DOI: 10.1016/S0006-8993(99)01372-4 [PubMed: 10366678]
22. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. *Brain Res.* 1995; 674(2):252–259. DOI: 10.1016/0006-8993(94)01449-R [PubMed: 7796104]
23. Munro G, Hansen R, Erichsen H, Timmermann D, Christensen J, Hansen H. The $\alpha 7$ nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. *Br J Pharmacol.* 2012; 167(2):421–435. DOI: 10.1111/j.1476-5381.2012.02003.x [PubMed: 22536953]
24. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. *NatRevNeurosci.* 2005; 6(1):48–56. DOI: 10.1038/nrn1588
25. Lockman PR, Allen DD. The transport of choline. *Drug Dev Ind Pharm.* 2002; 28(7):749–771. DOI: 10.1081/DDC-120005622 [PubMed: 12236062]
26. Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J. Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice. *Neurochem Int.* 2008; 52(6):972–978. DOI: 10.1016/j.neuint.2007.10.008 [PubMed: 18023504]
27. Gusev AG, Uteshev VV. Physiological concentrations of choline activate native $\alpha 7$ -containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea]. *J Pharmacol Exp Ther.* 2010; 332(2):588–598. DOI: 10.1124/jpet.109.162099 [PubMed: 19923442]
28. Uteshev VV, Meyer EM, Papke RL. Regulation of neuronal function by choline and 4OH-GTS-21 through $\alpha 7$ nicotinic receptors. *J Neurophysiol.* 2003; 89(4):1797–1806. DOI: 10.1152/jn.00943.2002 [PubMed: 12611953]
29. Klein J, Koppen A, Löffelholz K. Regulation of free choline in rat brain: dietary and pharmacological manipulations. *NeurochemInt.* 1998; 32(5-6):479–485. DOI: 10.1016/S0197-0186(97)00127-7
30. Papke RL, Papke JKP. Comparative pharmacology of rat and human $\alpha 7$ nAChR conducted with net charge analysis. *Br J of Pharmacol.* 2002; 137(1):49–61. DOI: 10.1038/sj.bjp.0704833 [PubMed: 12183330]
31. Uteshev VV, Stevens DR, Haas HL. α -Bungarotoxin-sensitive nicotinic responses in rat tuberomammillary neurons. *Pflugers Archiv-European Journal of Physiology.* 1996; 432(4):607–613. [PubMed: 8764960]

32. Uteshev VV, Meyer EM, Papke RL. Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. *Brain Res.* 2002; 948(1-2):33–46. DOI: 10.1016/S0006-8993(02)02946-3 [PubMed: 12383953]
33. Freitas K, Carroll FI, Damaj MI. The Antinociceptive Effects of Nicotinic Receptors alpha7-Positive Allosteric Modulators in Murine Acute and Tonic Pain Models. *J Pharmacol Exp Ther.* 2012; 344(1):264–275. DOI: 10.1124/jpet.112.197871 [PubMed: 23115222]
34. Lendvai B, Kassai F, Szajli A, Nemethy Z. alpha7 nicotinic acetylcholine receptors and their role in cognition. *Brain Res Bull.* 2013; 93:86–96. DOI: 10.1016/j.brainresbull.2012.11.003 [PubMed: 23178154]
35. Gasull T, DeGregorio-Rocasolano N, Zapata A, Trullas R. Choline release and inhibition of phosphatidylcholine synthesis precede excitotoxic neuronal death but not neurotoxicity induced by serum deprivation. *J Biol Chem.* 2000; 275(24):18350–18357. DOI: 10.1074/jbc.M910468199 [PubMed: 10748226]
36. Djuricic B, Olson SR, Assaf HM, Whittingham TS, Lust WD, Drewes LR. Formation of free choline in brain tissue during in vitro energy deprivation. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.* 1991; 11(2):308–313.
37. Kiewert C, Mdzinarishvili A, Hartmann J, Bickel U, Klein J. Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice. *Brain Res.* 2010; 1312:101–107. doi:10.1016/j.brainres.2009.11.068. doi:10.1016/j.brainres.2009.11.068. [PubMed: 19961839]
38. Bertrand N, Ishii H, Spatz M. Cerebral ischemia in young and adult gerbils: effects on cholinergic metabolism. *NeurochemInt.* 1996; 28(3):293–297. DOI: 10.1016/0197-0186(95)00086-0
39. Scremin OU, Jenden DJ. Time-dependent changes in cerebral choline and acetylcholine induced by transient global ischemia in rats. *Stroke.* 1991; 22(5):643–647. DOI: 10.1161/01.STR.22.5.643 [PubMed: 2028495]
40. Friedman SD, Brooks WM, Jung RE, Hart BL, Yeo RA. Proton MR spectroscopic findings correspond to neuropsychological function in traumatic brain injury. *AJNR American journal of neuroradiology.* 1998; 19(10):1879–1885. [PubMed: 9874540]
41. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. *JNeurosci.* 2005; 25(17):4396–4405. DOI: 10.1523/JNEUROSCI.5269-04.2005 [PubMed: 15858066]
42. McLean SL, Idris NF, Grayson B, Gendle DF, Mackie C, Lesage AS, Pemberton DJ, Neill JC. PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. *J Psychopharmacol.* 2012; 26(9):1265–1270. DOI: 10.1177/0269881111431747 [PubMed: 22182741]
43. Kalappa BI, Gusev AG, Uteshev VV. Activation of functional alpha7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596. *PloS one.* 2010; 5(11):e13964. doi: 10.1371/journal.pone.0013964 [PubMed: 21103043]
44. Badhan RK, Kaur M, Lungare S, Obuobi S. Improving brain drug targeting through exploitation of the nose-to-brain route: a physiological and pharmacokinetic perspective. *Curr Drug Deliv.* 2014; 11(4):458–471. DOI: 10.2174/1567201811666140321113555 [PubMed: 24655046]
45. Merkus FW, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. *Drugs R D.* 2007; 8(3):133–144. DOI: 10.2165/00126839-200708030-00001 [PubMed: 17472409]
46. Ren K, Puig V, Papke RL, Itoh Y, Hughes JA, Meyer EM. Multiple calcium channels and kinases mediate alpha7 nicotinic receptor neuroprotection in PC12 cells. *J Neurochem.* 2005; 94(4):926–933. DOI: 10.1111/j.1471-4159.2005.03223.x [PubMed: 15969741]
47. Shaw S, Bencherif M, Marrero MB. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. *J Biol Chem.* 2002; 277(47):44920–44924. DOI: 10.1074/jbc.M204610200 [PubMed: 12244045]

48. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. α 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A β -amyloid-induced neurotoxicity. *J Biol Chem*. 2001; 276(17):13541–13546. DOI: 10.1074/jbc.M008035200 [PubMed: 11278378]
49. Gubbins EJ, Gopalakrishnan M, Li J. α 7 nAChR-mediated activation of MAP kinase pathways in PC12 cells. *Brain Res*. 2010; 1328:1–11. DOI: 10.1016/j.brainres.2010.02.083 [PubMed: 20211606]
50. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. *Mov Disord*. 2012; 27(8):947–957. DOI: 10.1002/mds.25028 [PubMed: 22693036]
51. Jin K, Minami M, Lan JQ, Mao XO, Bateur S, Simon RP, Greenberg DA. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. *Proceedings of the National Academy of Sciences of the United States of America*. 2001; 98(8):4710–4715. DOI: 10.1073/pnas.081011098 [PubMed: 11296300]
52. Uteshev VV., Gusev, AG., Sametsky, EA. Network Control Mechanisms of Cellular Milieu. In: CF, BHF., editor. *Neuronal Networks in Brain Function*. Elsevier; USA: 2014. p. 135–141.
53. Pellicena P, Schulman H. CaMKII inhibitors: from research tools to therapeutic agents. *Frontiers in pharmacology*. 2014; 5:21.doi: 10.3389/fphar.2014.00021 [PubMed: 24600394]
54. Tischkau S, Mhaskar Y, Uteshev VV. Evidence for the exclusive expression of functional homomeric α 7 nAChRs in hypothalamic histaminergic tuberomammillary neurons in rats. *Neurosci Lett*. 2014; 563:107–111. DOI: 10.1016/j.neulet.2014.01.047 [PubMed: 24486841]
55. Gatson JW, Simpkins JW, Uteshev VV. High therapeutic potential of positive allosteric modulation of α 7 nAChRs in a rat model of traumatic brain injury: Proof-of-concept. *Brain Res Bull*. 2015; 112C:35–41. DOI: 10.1016/j.brainresbull.2015.01.008 [PubMed: 25647232]
56. Rosa AO, Egea J, Gandia L, Lopez MG, Garcia AG. Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the α 7 nAChR subtype. *J Mol Neurosci*. 2006; 30(1-2):61–62. DOI: 10.1385/JMN:30:1:61
57. van Meer G, de Kroon AI. Lipid map of the mammalian cell. *J Cell Sci*. 2011; 124(Pt 1):5–8. DOI: 10.1242/jcs.071233 [PubMed: 21172818]
58. Si ML, Lee TJ. Presynaptic α 7-nicotinic acetylcholine receptors mediate nicotine-induced nitric oxidergic neurogenic vasodilation in porcine basilar arteries. *J Pharmacol Exp Ther*. 2001; 298(1):122–128. [PubMed: 11408533]
59. Si ML, Lee TJ. α 7-nicotinic acetylcholine receptors on cerebral perivascular sympathetic nerves mediate choline-induced nitrenergic neurogenic vasodilation. *Circ Res*. 2002; 91(1):62–69. [PubMed: 12114323]
60. Egea J, Buendia I, Parada E, Navarro E, Leon R, Lopez MG. Anti-inflammatory role of microglial α 7 nAChRs and its role in neuroprotection. *Biochem Pharmacol*. 2015; 97(4):463–472. DOI: 10.1016/j.bcp.2015.07.032 [PubMed: 26232730]
61. Pavlov VA, Tracey KJ. Neural circuitry and immunity. *Immunol Res*. 2015; 63:38–57. DOI: 10.1007/s12026-015-8718-1 [PubMed: 26512000]
62. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. Cholinergic modulation of microglial activation by α 7 nicotinic receptors. *J Neurochem*. 2004; 89(2):337–343. DOI: 10.1046/j.1471-4159.2004.02347.x [PubMed: 15056277]
63. De Rosa MJ, Dionisio L, Agriello E, Bouzat C, Esandi Mdel C. α 7 nicotinic acetylcholine receptor modulates lymphocyte activation. *Life Sci*. 2009; 85(11-12):444–449. DOI: 10.1016/j.lfs.2009.07.010 [PubMed: 19632243]
64. Tracey KJ. The inflammatory reflex. *Nature*. 2002; 420(6917):853–859. DOI: 10.1038/nature01321 [PubMed: 12490958]
65. Guerra-Alvarez M, Moreno-Ortega AJ, Navarro E, Fernandez-Morales JC, Egea J, Lopez MG, Cano-Abad MF. Positive allosteric modulation of α 7 nicotinic receptors promotes cell death by inducing Ca^{2+} release from the endoplasmic reticulum. *J Neurochem*. 2015; 133(3):309–319. DOI: 10.1111/jnc.13049 [PubMed: 25650007]
66. Hu M, Gopalakrishnan M, Li J. Positive allosteric modulation of α 7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons. *Br J*

- Pharmacol. 2009; 158(8):1857–1864. DOI: 10.1111/j.1476-5381.2009.00474.x [PubMed: 20050184]
67. Lukas RJ, Lucero L, Buisson B, Galzi JL, Puchacz E, Fryer JD, Changeux JP, Bertrand D. Neurotoxicity of channel mutations in heterologously expressed $\alpha 7$ -nicotinic acetylcholine receptors. *Eur J Neurosci.* 2001; 13(10):1849–1860. DOI: 10.1046/j.0953-816x.2001.01560.x [PubMed: 11403678]
68. Uteshev V. Are positive allosteric modulators of $\alpha 7$ nAChRs clinically safe? *J Neurochem.* 2015; doi: 10.1111/jnc.13236
69. Williams DK, Peng C, Kimbrell MR, Papke RL. Intrinsically low open probability of $\alpha 7$ nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures. *Mol Pharmacol.* 2012; 82(4):746–759. DOI: 10.1124/mol.112.080317 [PubMed: 22828799]
70. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, Gee KW. Nootropic $\alpha 7$ nicotinic receptor allosteric modulator derived from GABAA receptor modulators. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104(19):8059–8064. DOI: 10.1073/pnas.0701321104 [PubMed: 17470817]

Figure 1. Cerebral blood flow measurements

A typical example of regional cerebral blood flow (rCBF) measurements before, during and after tMCAO. In these experiments, the rCBF was continuously recorded and evaluated using Laser-Doppler flowmeter (see the subsection *Materials and Methods*) before and during occlusion of the common carotid artery (CCAO), and then, during and after tMCAO as a percent of the mean baseline value recorded over the last 5 min before CCAO (i.e., 100%). A successful 90 min MCAO was defined as an abrupt sustained reduction in rCBF by at least 70% followed by a recovery to the flow level corresponding to CCAO.

Figure 2. Evaluation of PNU levels in brain and blood samples using mass spectrometry
 Samples of blood as well as cortical and striatal tissues were collected 3 hrs after i.n. injection of 10 mg/kg PNU (see *Methods*). **A**) Full mass spectrum of PNU showing a $[M+H]^+$ at m/z 312.1 and the 2 Dalton shift due to chloride at 314.1. The structure shown is one possible protonated molecule. **B**) Production mass spectrum of PNU showing unique fragment ions from a collision induced dissociation at 25 V. The product ions structures are theoretical fragments using distonic ion formations and the following common reactions: resonance reactions, ring formations and hydride shifts. **C**) A typical calibration curve for the determination of PNU in tissue and plasma samples. The standards were run at the following concentrations: 0.3, 1.0, 2.5, 5.0, 10, 25, 50, 100, 200 and 250 ng/mL. **D**) Typical chromatograms for the determination of PNU in tissue. The Q1/Q3 m/z 312/173 was used as the quantitation ion while the Q1/Q3 m/z 312/188 and Q1/Q3 m/z 312/158 were used for further confirmation.

Figure 3. Endogenous $\alpha 7$ -dependent protection after tMCAO: ischemic infarct volume Methyllycaconitine (MLA; s.c, 10 mg/kg), a selective $\alpha 7$ nAChR antagonist, failed to significantly increase infarct volume after a 90 min tMCAO (unpaired, two-tail Student's t-test, $t=0.3572$, $df=12$, $p=0.7271$, 95% CI: -10.75, 7.72, $n=6-8$; **A-B**) suggesting that $\alpha 7$ activation does not significantly saves neurons in the absence of PNU in this experimental paradigm (*circles* vs. *squares*; **B**). These results also suggested that ischemic brain injury resulting from a 90 min tMCAO is too extensive (~45%; **A-B**) and the use of PNU-like $\alpha 7$ -PAMs is absolutely required to achieve significant $\alpha 7$ -dependent protection in these settings. To test whether a less severe injury is more receptive to endogenous protective mechanisms, we used a 60 min tMCAO. Reducing the duration of tMCAO from 90 min to 60 min resulted

in a ~50% reduction of infarct volume (~22% vs. ~45%; *circles*; **B** and **D**). MLA significantly increased infarct volume after a 60 min tMCAO from 20% to 35% (unpaired, two-tail Student's t-test, $t=2.272$, $df=14$, $p=0.0393$, 95% CI: 0.7724, 26.72, $n=7-9$; **C-D**), an increase of ~75% (*circles* vs. *squares*; **D**), indicating that endogenous $\alpha 7$ -dependent protection is greater after a less severe ischemic injury.

Figure 4. Endogenous $\alpha 7$ -dependent protection after tMCAO: behavioral tests

The results of behavioral tests were consistent with infarct volume data: MLA (*squares* as compared to *circles*; i.e., vehicle groups) failed to produce significant neurological deficits after a 90 min tMCAO (unpaired, two-tailed Mann-Whitney, $n=11-12$; **A-C**): Bederson ($p=0.3556$, 95% CI: 0.0, 1.0); cylinder ($p=0.6127$, 95% CI: -10.0, 2.5) and limb placing ($p=0.4478$, 95% CI: -1.0, 0.0). By contrast, significant neurological deficits after MLA treatment were detected in two tests after a 60 min tMCAO (unpaired, two-tailed Mann-Whitney, $n=11-12$; **D-E**): Bederson ($p=0.0427$, 95% CI: 0.0, 2.0) and cylinder ($p=0.0227$, 95% CI: -45.0, 0.0). The remaining test (limb placing) conducted after a 60 min tMCAO failed to detect significant differences between MLA-treated and control groups: $p=0.5940$, 95% CI: -7.0, 2.0 (**F**).

Figure 5. Significant brain protection by i.n. PNU

Animals were subjected to a 90 min tMCAO and randomly assigned to 3 groups treated with i.n. vehicle or i.n. PNU (10 mg/kg) 30 min after the tMCAO onset with or without MLA pretreatment (i.e., PNU±MLA groups). Infarct volume and neurological deficits were determined 24 hrs after tMCAO. I.N. PNU significantly reduced infarct volume (one-way ANOVA with individual F-test comparisons; $F(2,12)=9.730$, $p=0.0031$, $n=5$; *squares vs. circles*; **A-B**) and neurological deficits (Kruskal-Wallis with Dunn's multiple comparisons test; **C-E**) in control ($n=10$) vs. PNU-treated ($n=13$) groups in the following behavioral tests: Bederson ($H=23.00$, $p<0.0001$; **C**); cylinder ($H=20.94$, $p<0.0001$; **D**) and limb placing

($H=25.85$, $p<0.0001$; **E**). The corresponding post-tests multiple comparison tests detected the following levels of significance among vehicle- and PNU-treated groups: infarct volume ($t=3.889$, $df=12$, $p=0.0022$), Bederson ($p=0.0002$); cylinder ($p=0.0036$) and limb placing ($p<0.0001$). These effects of PNU were reversed by MLA (s.c. 10 mg/kg; $n=12$) injected 10 min after tMCAO onset (*triangles vs. squares*) as evidenced from significant effects produced by MLA (i.e., PNU vs. PNU+MLA groups) in all tests: i.e., infarct volume ($t=3.748$, $df=12$, $p=0.0028$); Bederson ($p=0.0001$); cylinder ($p<0.0001$); and limb placing ($p<0.0001$). Significant differences were not detected between control and MLA-treated groups in all tests ($p>0.05$, *circles vs. triangles*, **B-E**).

Figure 6. KN93 inhibits protective effects of i.n. PNU

I.C.V. infusion of KN93 completely eliminated protective effects of i.n. PNU after a 90 min tMCAO, as evidenced by statistically significant changes in infarct volume (one-way ANOVA with individual F-test comparisons; $F(2,14)=5.522$, $p=0.0171$, $n=5-7$; **A-B**) and neurological deficits (Kruskal-Wallis with Dunn's multiple comparisons test; **C-E**) among PNU-, PNU+KN92 and PNU+KN93-treated groups ($n=8-9$) in the following behavioral tests: Bederson ($H=8.798$, $p=0.0123$; **C**); cylinder ($H=13.27$, $p=0.0013$; **D**) and limb placing ($H=11.81$, $p=0.0027$; **E**). The corresponding post-tests multiple comparison tests detected

the following levels of significance among PNU- and PNU+KN93-treated groups (*circles vs. squares*): infarct volume ($t=2.943$, $df=14$, $p=0.0107$), Bederson ($p<0.05$); cylinder ($p<0.05$) and limb placing ($p<0.05$). A similar i.c.v. treatment with KN92, an inactive analogue of KN93, failed to significantly alter the effects of PNU in all tests ($p>0.05$; *open vs. hatched columns*, **B-E**). Accordingly, significant differences were detected between PNU+KN92 and PNU+KN93 groups in all tests ($p<0.05$; *triangles vs. squares*, **B-E**). A statistically significant increase in infarct volume (**F-G**) was detected after i.c.v. KN93 treatment alone (i.e., without PNU) (unpaired, two-tailed Student's t-test; $t=2.373$, $df=9$, $p=0.0417$, 95% CI: 0.4539, 18.97, $n=5-6$; *circles vs. squares*, **H**) supporting the presence of endogenous $\alpha 7$ -dependent protection after tMCAO.

Figure 7. KN93 does not directly block α 7 nAChRs. To test whether KN93 directly blocks α 7 nAChRs, electrophysiological patch-clamp recordings of α 7 nAChR-mediated responses were conducted using hypothalamic TM neurons that express high densities of native functional α 7 nAChRs[54,31]. Acute hypothalamic slices were pre-incubated in 1 μ M PNU for 50 min to equilibrate the concentration of PNU within the slice. An addition of 20 μ M choline to the ACSF produced a clearly detectable persistent whole-cell current (**A**) that stabilized shortly after initiation. KN93 (20 μ M) was dissolved in ACSF containing 1 μ M PNU +20 μ M choline and focally applied by pressure. **B**) Prolonged pressure puffs (12 s duration at 10 psi) of KN93 (gray box above current traces) did not inhibit the level of persistent α 7 nAChR activation. On the contrary, a small but significant increase in the current levels was detected (**C**). Data were recorded from n=6 TM neurons obtained from m=2 preparations/rats. The level of activation was quantified by measuring the mean current over the time windows with equal duration: i.e., T1 (12 s prior to KN93) and T2 (12 s during KN93) (**B**).